Top

Published in:

01-06-2014 | Educational Series - Blue Series

Cancer cell resistance mechanisms: a mini review

Authors: S. Al-Dimassi, T. Abou-Antoun, M. El-Sibai

Published in: Clinical and Translational Oncology | Issue 6/2014

Abstract

Cancer is a leading cause of death worldwide accounting to 13 % of all deaths. One of the main causes behind the failure of treatment is the development of various therapy resistance mechanisms by the cancer cells leading to the recurrence of the disease. This review sheds a light on some of the mechanisms developed by cancer cells to resist therapy as well as some of the structures involved such as the ABC members’ involvement in chemotherapy resistance and MET and survivin overexpression leading to radiotherapy resistance. Understanding those mechanisms will enable scientists to overcome resistance and possibly improve treatment and disease prognosis.

Garcia M, Jemal A. Global cancer facts and figures. Atlanta: American Cancer Society; 2007.

Baskar R, Lee KA, Yeo R, Yeoh K-W. Cancer and radiation therapy: current advances and future directions. Int J Med Sci. 2012;9(3):193–9. doi:10.7150/ijms.3635.PubMedCentralPubMedCrossRef

American Cancer Society. Cancer facts and figures 2013. Atlanta: American Cancer Society; 2013. p 2013.

Dalkic E, Wang X, Wright N, Chan C. Cancer-drug associations: a complex system. PLoS One. 2010;5(4):e10031. doi:10.1371/journal.pone.0010031.PubMedCentralPubMedCrossRef

Hanahan D, Weinberg R. Hallmarks of cancer: the next generation. Cell. 2011;144(5):646–74. doi:10.1016/j.cell.2011.02.013.PubMedCrossRef

Bhosle J, Hall G. Principles of cancer treatment by chemotherapy. Surgery (Oxford). 2009;27(4):173–7.CrossRef

Borst P, Elferink R. Mammalian ABC transporters in health and disease. Annu Rev Biochem. 2002;71:537–92. doi:10.1146/annurev.biochem.71.102301.093055.PubMedCrossRef

Dean M, Hamon Y, Chimini G. The human ATP-binding cassette (ABC) transporter superfamily. J of Lipid Res. 2001;11(7):1156–66.

Lubelski J, Konings W, Driessen A. Distribution and physiology of ABC-type transporters contributing to multidrug resistance in bacteria. Micro Mol Bio Rev. 2007;71(3):463–76. doi:10.1128/MMBR.00001-07.CrossRef

10.

Chen J, Lu G, Davidson A, Qutocho F. A tweezers-like motion of the ATP-binding cassette dimer in an ABC transport cycle. Moll Cell. 2003;12(3):651–61.CrossRef

11.

Sarkadi B, Homolya L, Szakacs G, Varadi A. Human multidrug resistance ABCB and ABCG transporters: participation in a chemoimmunity defense system. Physiol Rev. 2006;86(4):1179–236. doi:10.1152/physrev.00037.2005.PubMedCrossRef

12.

Huff L, J-S LEE, Robey R, Fojo T. Characterization of gene rearrangements leading to activation of MDR-1. J Biol Chem. 2006;281(48):365019. doi:10.1074/jbc.M602998200.CrossRef

13.

Stavrovskaya A, Stromskaya T. Transport proteins of the ABC family and multidrug resistance of tumor cells. Biochemistry. 2008;73(5):592–604. doi:10.1134/S0006297908050118.PubMed

14.

Davidson A, Elie D, Orelle C, Chen J. Structure, function, and evolution of bacterial ATP-binding cassette systems. Microbiol mol bio rev. 2008;72(2):317–64. doi:10.1128/MMBR.00031-07.CrossRef

15.

Hipfner D, Deeley R, Cole S. Structural, mechanistic and clinical aspects of MRP1. Biochim Biophys Acta. 1999;1461(2):359–76. doi:10.1016/S0005-2736(99)00168-6.PubMedCrossRef

16.

Schwab M, Eichelbaum M, Fromm M. Genetic polymorphisms of the human MDR1 drug transporter. Annu Rev Pharmacol Toxicol. 2003;43:285–307. doi:10.1146/annurev.pharmtox.43.100901.140233.PubMedCrossRef

17.

González-Pons M, Szeto A, González-Méndez R, Serrano A. Identification and bioinformatic characterization of a multidrug resistance associated protein (ABCC) gene in Plasmodium berghei. Malar J. 2009;8:1. doi:10.1186/1475-2875-8-1.PubMedCentralPubMedCrossRef

18.

Leslie E, Deeley R, Cole S. Multidrug resistance proteins: role of P-glycoprotein, MRP1, MRP2, and BCRP (ABCG2) in tissue defense. Toxicol Appl Pharm. 2005;204(3):216–37. doi:10.1016/j.taap.2004.10.012.CrossRef

19.

Yin J-Y, Huang Q, Yang Y, Zhang J-T, Zhong M-Z, Zhou H–H, et al. Characterization and analyses of multidrug resistance-associated protein 1 (MRP1/ABCC1) polymorphisms in Chinese population. Pharmacogenet Genomics. 2009;19(3):206–16. doi:10.1097/FPC.0b013e328323f680.PubMedCentralPubMedCrossRef

20.

Kyle-Cezar F, Echevarria-Lima J, Goldenberg R, Rumjanek V. Expression of c-kit and Sca-1 and their relationship with multidrug resistance protein 1 in mouse bone marrow mononuclear cells. Immunology. 2007;121(1):122–8. doi:10.1111/j.1365-2567.2007.02547.x.PubMedCentralPubMedCrossRef

21.

Akan I, Akan S, Akca H, Savas B, Ozben T. Multidrug resistance-associated protein 1 (MRP1) mediated vincristine resistance: effects of N-acetylcysteine and Buthionine sulfoximine. Cancer Cell Int. 2005;5:22. doi:10.1186/1475-2867-5-22.PubMedCentralPubMedCrossRef

22.

Kasinathan R, Morgan W, Greenberg R. Schistosoma mansoni express higher levels of multidrug resistance-associated protein 1 (SmMRP1) in juvenile worms and in response to praziquantel. Mol Biochem Parasitol. 2010;173(1):25–31. doi:10.1016/j.molbiopara.2010.05.003.PubMedCentralPubMedCrossRef

23.

Mao Q, Unadkat J. Role of the breast cancer resistance protein (ABCG2) in drug transport. AAPS Journal. 2005;7(1):E118–33. doi:10.1208/aapsj070112.PubMedCentralPubMedCrossRef

24.

Marchan R, Hammond C, Ballatori N. Multidrug resistance-associated protein 1 as a major mediator of basal and apoptotic glutathione release. Biochim Biophys Acta. 2008;1778(10):2413–20. doi:10.1016/j.bbamem.2008.06.011.PubMedCentralPubMedCrossRef

25.

Mao Q, Unadkat J. Role of the breast cancer resistance protein (ABCG2) in drug transport. AAPS J. 2005;7(1):E118–33. doi:10.1208/aapsj070112.PubMedCentralPubMedCrossRef

26.

Zhu M, Tong J, Xu Q, Nie F, Xu X, Xiao S, et al. Increased JNK1 signaling pathway is responsible for ABCG2-mediated multidrug resistance in human colon cancer. PLoS One. 2012;7(8):e41763. doi:10.1371/journal.pone.0041763.PubMedCentralPubMedCrossRef

27.

Li X, Pan Y-Z, Seigel G, Hu Z-H, Huang M, Yu A-M. Breast cancer resistance protein BCRP/ABCG2 regulatory microRNAs (hsa-miR-328, -519c and -520 h) and their differential expression in stem-like ABCG2+ cancer cells. Biochem Pharmacol. 2011;81(6):783–92. doi:10.1016/j.bcp.2010.12.018.PubMedCentralPubMedCrossRef

28.

Mo W, Zhang J-T. Human ABCG2: structure, function, and its role in multidrug resistance. Int J Biochem Mol Biol. 2012;3(1):1–27.PubMedCentralPubMed

29.

Begg A, Stewart F, Vens C. Strategies to improve radiotherapy with targeted drugs. Nat Rev Cancer. 2011;11:239–53. doi:10.1038/nrc3007.PubMedCrossRef

30.

Ghisolfi L, Keates A, Hu X, Lee D-k, Li C. Ionizing radiation induces stemness in cancer cells. PLoS One. 2012;7(8):e43628. doi:10.1371/journal.pone.0043628.PubMedCentralPubMedCrossRef

31.

Suit H. Local control and patient survival. Int J of Rad Oncol Bio Phys. 1992;23(3):653–60. doi:10.1016/0360-3016(92)90025-D.CrossRef

32.

Barcellos-Hoff M, Park C, Wright E. Radiation and the microenvironment—tumorigenesis and therapy. Nat Rev Cancer. 2005;5:867–75. doi:10.1038/nrc1735.PubMedCrossRef

33.

Shiloh Y. ATM and related protein kinases: safeguarding genome integrity. Nat Rev Cancer. 2003;3(3):155–68. doi:10.1038/nrc1011.PubMedCrossRef

34.

Trusolino L, Comoglio P. Scatter-factor and semaphorin receptors: cell signalling for invasive growth. Nat Rev Cancer. 2002;2(4):289–300. doi:10.1038/nrc779.PubMedCrossRef

35.

De Bacco F, Luraghi P, Medico E, Reato G, Girolami F, Perera T, et al. Induction of MET by ionizing radiation and its role in radioresistance and invasive growth of cancer. J Natl Cancer Inst. 2011;103(8):645–661. doi:10.1093/jnci/djr093.PubMedCrossRef

36.

Inanami O, Takahashi K, Kuwabara M. Attenuation of caspase-3-dependent apoptosis by Trolox post-treatment of X-irradiated MOLT-4 cells. Int J of Rad Bio. 1999;75(2):155–63. doi:10.1080/095530099140609.CrossRef

37.

Ambrosini G, Adida C, Altieri D. A novel anti-apoptosis gene, survivin, expressed in cancer and lymphoma. Nat Med. 1997;3:917–21. doi:10.1038/nm0897-917.PubMedCrossRef

38.

Asanuma K, Moriai R, Yajima T, Yagihashi A, Yamada M, Kobayashi D, et al. Survivin as a radioresistance factor in pancreatic cancer. Jpn J Cancer Res. 2000;91(11):1204–9. doi:10.1111/j.1349-7006.2000.tb00906.x.PubMedCrossRef

39.

Dillman R, Fogel GB, Cornforth AN, Selvan SR, Schiltz PM, DePriest C. Features associated with survival in metastatic melanoma patients treated with patient-specific dendritic cell vaccines. Cancer Biother Radiopharm. 2011;26(4):407–15. doi:10.1089/cbr.2011.0973.PubMedCrossRef

40.

Dunn G, Old L, Schreiber R. The immunobiology of cancer immunosurveillance and immunoediting. Immunity. 2004;21(2):137–48. doi:10.1016/j.immuni.2004.07.017.PubMedCrossRef

41.

Schreiber R, Old L, Smyth M. Cancer immunoediting: integrating immunity’s roles in cancer suppression and promotion. Science. 2011;331:1565–70. doi:10.1126/science.1203486.PubMedCrossRef

42.

Marincola F, Jaffee E, Hicklin D, Ferrone S. Escape of human solid tumors from T–cell recognition: molecular mechanisms and functional significance. Adv Immuno. 2000;74:181–273. doi:10.1016/S0065-2776(08)60911-6.CrossRef

43.

Ribas A, Butterfield L, Glaspy J, Economou J. Current developments in cancer vaccines and cellular immunotherapy. J of Clin Oncol. 2003;21(12):2415–32. doi:10.1200/JCO.2003.06.041.CrossRef

Title: Cancer cell resistance mechanisms: a mini review
Authors: S. Al-Dimassi
T. Abou-Antoun
M. El-Sibai
Publication date: 01-06-2014
Publisher: Springer Milan
Published in: Clinical and Translational Oncology / Issue 6/2014
Print ISSN: 1699-048X
Electronic ISSN: 1699-3055
DOI: https://doi.org/10.1007/s12094-014-1162-1

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 6/2014

Concurrent chemoradiotherapy with low-dose docetaxel inhibits the growth of DU-145 prostate cancer xenografts

High interstitial fluid pressure promotes tumor progression through inducing lymphatic metastasis-related protein expressions in oral squamous cell carcinoma

Final results of a phase II single-institutional trial with hyperfractionated radiation therapy (HFX) and four-weekly continuous cisplatin in locally advanced head and neck carcinoma

Tumor histological subtyping determined by hormone receptors and HER2 status defines different pathological complete response and outcome to dose-dense neoadjuvant chemotherapy in breast cancer patients

Lung cancer in women: an overview with special focus on Spanish women

Peroxiredoxin 3 is resistant to oxidation-induced apoptosis of Hep-3b cells

Keynote webinar | Spotlight on antibody–drug conjugates in cancer